Background. Papillary thyroid carcinoma (PTC) usually has an indolent clinical course, yet a subset of patients might show an aggressive course. Thus, better stratification of at-risk patients is mandatory for proper management. Solute carrier family 34 member 2 (SLC34A2) is an independent prognostic indicator in several cancers. However, only a few studies have been conducted to evaluate the prognostic value of SLC34A2 in PTC, with none of them assessing its immunohistochemical (IHC) expression in a large cohort of patients with PTC or exploring its possible relationship with tumor progression. Aim of the Study. We aimed to evaluate the IHC expression of SLC34A2 in a large series of PTC patients, correlate its expression with established clinicopathological factors, and find any possible relationship between this marker and patient prognosis. Material and Methods. A total of 476 samples (including 238 samples of PTC and 238 samples of normal thyroid tissue) collected between 2002 and 2005 were extracted from the archives of the Pathology Lab, Ain Shams University Hospitals. IHC analysis was performed using an anti-SLC34A2 antibody. Follow-up data were obtained. Results. High SLC34A2 expression significantly correlated with important adverse clinicopathological parameters of PTC—i.e., late tumor stage, positive extrathyroid extension, tumor size > 4 cm, and age ≥ 55 years ( for each). Kaplan–Meier analysis revealed that high SLC34A2 expression significantly correlated with shorter disease-free survival (DFS; ), but not with overall survival (). Multivariate analysis showed SLC34A2 to be an independent prognostic factor affecting DFS. Conclusions. High SLC34A2 IHC expression correlated with adverse clinicopathological prognostic parameters. Furthermore, SLC34A2 was identified as an independent factor for DFS that could serve to improve risk stratification of PTC patients for better management.

中文翻译：

---

溶质载体家族 34 成员 2“SLC34A2”在甲状腺乳头状癌中的预后价值评估：一项免疫组织化学研究

背景。甲状腺乳头状癌 (PTC) 通常具有惰性临床病程，但一部分患者可能表现出侵袭性病程。因此，对高危患者进行更好的分层对于适当的管理是强制性的。溶质载体家族 34 成员 2 (SLC34A2) 是几种癌症的独立预后指标。然而，只有少数研究评估了 SLC34A2 在 PTC 中的预后价值，没有一项研究评估其在大量 PTC 患者中的免疫组织化学 (IHC) 表达或探索其与肿瘤进展的可能关系。研究目的. 我们旨在评估大量 PTC 患者中 SLC34A2 的 IHC 表达，将其表达与已确定的临床病理因素相关联，并发现该标志物与患者预后之间的任何可能关系。材料和方法。从 Ain Shams 大学医院病理实验室的档案中提取了 2002 年至 2005 年期间收集的总共 476 个样本（包括 238 个 PTC 样本和 238 个正常甲状腺组织样本）。使用抗 SLC34A2 抗体进行 IHC 分析。获得了后续数据。结果。SLC34A2 高表达与 PTC 的重要不良临床病理参数显着相关，即肿瘤晚期、甲状腺外扩散阳性、肿瘤大小 > 4 cm 和年龄 ≥ 55 岁。每个）。Kaplan-Meier 分析显示，高 SLC34A2 表达与较短的无病生存期（DFS；)，但与总生存期无关 (）。多变量分析显示 SLC34A2 是影响 DFS 的独立预后因素。结论。高 SLC34A2 IHC 表达与不良临床病理学预后参数相关。此外，SLC34A2 被确定为 DFS 的独立因素，可用于改善 PTC 患者的风险分层以更好地管理。